# Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

> **NCT03939312** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 685 (actual)

## Conditions studied

- Episodic Migraine

## Interventions

- **DRUG:** Atogepant

## Key facts

- **NCT ID:** NCT03939312
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-06
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 685 (ACTUAL)
- **Last updated:** 2022-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03939312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03939312, "Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03939312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*